ArticleThe Journal of allergy and clinical immunology2013
Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity.
Article in The Journal of allergy and clinical immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it, 214 citations in OpenAlex.
- Unveiling the functional paradigm of exosome-derived long non-coding RNAs (lncRNAs) in cancer: based on a narrative review and systematic review.Journal of cancer research and clinical oncology · 2023Pooled it
- Molecular Signature and miRNA Pattern of CD4 + T Lymphocytes in Plaque Psoriasis.Clinical reviews in allergy & immunology · 2026Review
- The Potentials of Stem Cell-Derived Exosomal MicroRNAs in Ferroptosis Modulation: Molecular Insights into Hepatoprotection, Neuroprotection, Cardioprotection, Renoprotection and Pulmonoprotection.Stem cell reviews and reports · 2026Review
- Engineered small extracellular vesicles as bioactive materials: Integrating engineering strategies for cargo loading and targeted delivery systems.Bioactive materials · 2026Review
- mTOR Signaling in Macrophages: All Depends on the Context.International journal of molecular sciences · 2025Review
- Extracellular Vesicle (EV) Targeted Cells Release Secondary Effector EVs: Indication of How To Account for Histocompatibility and Disease Specificity of EV Treatments.Journal of extracellular vesicles · 2025Review
- Is Nasal Dysbiosis a Required Component for Neuroinflammation in Major Depressive Disorder?Molecular neurobiology · 2025Review
- Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Nanovesicles Alleviated Colitis via Modulating Th17/Treg Balance Through Hsa-miR-27b-3p-Mediated Suppression of PI3K/AKT/STAT3 Signaling Pathway.International journal of nanomedicine · 2025Article
- Role of exosomes in gastrointestinal physiology and pathophysiology.Frontiers in immunology · 2025Review
- Unlocking the potential of miRNAs in detecting pulmonary tuberculosis: prospects and pitfalls.Expert reviews in molecular medicine · 2024Review
- MicroRNA Nano-Shuttles: Engineering Extracellular Vesicles as a Cutting-Edge Biotechnology Platform for Clinical Use in Therapeutics.Biological procedures online · 2024Review
- Macrophage Functions in Psoriasis: Lessons from Mouse Models.International journal of molecular sciences · 2024Review
- Mast Cells in Autism Spectrum Disorder-The Enigma to Be Solved?International journal of molecular sciences · 2024Review
- Assessment of the Antigen-Binding Capacity and Separation of Extracellular Vesicles Coated with Antigen-Specific Antibody Light Chains.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Engineering of Cell Derived-Nanovesicle as an Alternative to Exosome Therapy.Tissue engineering and regenerative medicine · 2024Review
- Extracellular Vesicles from Immune Cells: A Biomedical Perspective.International journal of molecular sciences · 2023Review
- Exosomes: Promising Delivery Tools for Overcoming Blood-Brain Barrier and Glioblastoma Therapy.Molecular neurobiology · 2023Review
- Extracellular vesicles and COPD: foe or friend?Journal of nanobiotechnology · 2023Review
- Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances.Acta pharmaceutica Sinica. B · 2023Review
- Genetically engineered CXCR4-modified exosomes for delivery of miR-126 mimics to macrophages alleviate periodontitis.Journal of nanobiotechnology · 2023Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundT-cell tolerance of allergic cutaneous contact sensitivity (CS) induced in mice by high doses of reactive hapten is mediated by suppressor cells that release antigen-specific suppressive nanovesicles.
objectiveWe sought to determine the mechanism or mechanisms of immune suppression mediated by the nanovesicles.
methodsT-cell tolerance was induced by means of intravenous injection of hapten conjugated to self-antigens of syngeneic erythrocytes and subsequent contact immunization with the same hapten. Lymph node and spleen cells from tolerized or control donors were harvested and cultured to produce a supernatant containing suppressive nanovesicles that were isolated from the tolerized mice for testing in active and adoptive cell-transfer models of CS.
resultsTolerance was shown due to exosome-like nanovesicles in the supernatants of CD8(+) suppressor T cells that were not regulatory T cells. Antigen specificity of the suppressive nanovesicles was conferred by a surface coat of antibody light chains or possibly whole antibody, allowing targeted delivery of selected inhibitory microRNA (miRNA)-150 to CS effector T cells. Nanovesicles also inhibited CS in actively sensitized mice after systemic injection at the peak of the responses. The role of antibody and miRNA-150 was established by tolerizing either panimmunoglobulin-deficient JH(-/-) or miRNA-150(-/-) mice that produced nonsuppressive nanovesicles. These nanovesicles could be made suppressive by adding antigen-specific antibody light chains or miRNA-150, respectively.
conclusionsThis is the first example of T-cell regulation through systemic transit of exosome-like nanovesicles delivering a chosen inhibitory miRNA to target effector T cells in an antigen-specific manner by a surface coating of antibody light chains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.